DOCSLIB.ORG

Deep Brain Stimulation in the Treatment of Dyskinesia and Dystonia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Deep Brain Stimulation in the Treatment of Dyskinesia and Dystonia Neurosurg Focus 17 (1):E2, 2004, Click here to return to Table of Contents Deep brain stimulation in the treatment of dyskinesia and dystonia HIROKI TODA, M.D., PH.D., CLEMENT HAMANI, M.D., PH.D., AND ANDRES LOZANO, M.D., PH.D., F.R.C.S.(C) Division of Neurosurgery, Department of Surgery, Toronto Western Hospital, University of Toronto, Ontario, Cananda Deep brain stimulation (DBS) has become a mainstay of treatment for patients with movement disorders. This modality is directed at modulating pathological activity within basal ganglia output structures by stimulating some of their nuclei, such as the subthalamic nucleus (STN) and the globus pallidus internus (GPi), without making permanent lesions. With the accumulation of experience, indications for the use of DBS have become clearer and the effective- ness and limitations of this form of therapy in different clinical conditions have been better appreciated. In this review the authors discuss the efficacy of DBS in the treatment of dystonia and levodopa-induced dyskinesias. The use of DBS of the STN and GPi is very effective for the treatment of movement disorders induced by levodopa. The relative ben- efits of using the GPi as opposed to the STN as a target are still being investigated. Bilateral GPi stimulation is gain- ing importance in the therapeutic armamentarium for the treatment of dystonia. The DYT1 forms of generalized dys- tonia and cervical dystonias respond to DBS better than secondary dystonia does. Discrimination between the diverse forms of dystonia and a better understanding of the pathophysiological features of this condition will serve as a plat- form for improved outcomes. KEY WORDS • dystonia • dyskinesia • Parkinson disease • deep brain stimulation • stereotactic neurosurgery Long-term electrical stimulation is being used increas- movements that are caused by long-term medication treat- ingly in patients with movement disorders whose disabil- ment and disease progression. Both lesioning and high- ity continues despite medical treatment. Because of its frequency stimulation in the GPi and STN can be effective effectiveness and potential reversibility, in many regions in the treatment of these abnormal movements. of the world DBS has gradually replaced lesioning proce- Stimulation of the STN. The improvement in dyskine- dures for the treatment of PD, dystonia, and essential sias after DBS of the STN is probably related to two tremor. With the accumulation of experience, the indica- mechanisms: the first is the reduction in medication that tions for DBS have become clearer and the effectiveness often occurs after surgery and the second is a direct anti- and limitations of this form of therapy are being better dyskinetic effect. The mean levodopa-equivalent dose appreciated. Although DBS has multiple applications, we intake used preoperatively is reduced by 50 to 60% after will limit this discussion to DBS for dyskinesias induced DBS of STN.5,24,29,30,52,56,62,66,77,80 Along with this reduction in by levodopa therapy and for dystonia. medications, Unified PD Rating Scale Part IV (complica- tions of therapy) scores improve by 70 to 95% after 6 months in patients treated with STN stimulation.5,66,80 The USE OF DBS FOR LEVODOPA-INDUCED duration of dyskinesias is reduced by 70 to 85% after DBS DYSKINESIAS of the STN and there are significant improvements in both disability (by 58–93%), and motor fluctuations (by Dyskinesias induced by long-term levodopa therapy 5,16,24,29,30,33,48,52,56,62,70,75 represent one of the major limitations in the treatment 45–61%). The improvement in dyski- nesias is sustained at 5 years after surgery of the STN for of patients with PD. These involuntary choreiform and 30 dystonic drug-induced movements constitute a common DBS. problem for which the incidence is as high as 80% after 5 Stimulation of the GPi. Stimulation of the GPi has a years of treatment.58 Most patients with PD who have dys- strong, direct effect on reducing or eliminating levodopa- kinesias become significantly disabled by these abnormal induced dyskinesias that is independent of any reduction in medications after surgery.16–18,31,79 There is a 65 to 75% reduction in dyskinesia scores, and the duration of these symptoms throughout the day improves by 65 to 70% at 3 16,17,31,79 Abbreviations used in this paper: DBS = deep brain stimulation; to 6 months after pallidal DBS. The 50% reduction GP = globus pallidus; GPe = GP externus; GPi = GP internus; in dyskinesia scores remained at 3 years after pallidal PD = Parkinson disease; STN = subthalamic nucleus. DBS.18 Neurosurg. Focus / Volume 17 / July, 2004 9 Unauthenticated | Downloaded 09/30/21 03:05 PM UTC H. Toda, C. Hamani, and A. Lozano The relationship between the location of the stimulating musculature that lead to twisting and abnormal postures of 36 electrode’s contacts in the GP and the clinical effect of the neck. Dopamine D5 receptor dysfunction has been DBS is somewhat complex and controversial. The best implicated in this disorder.8,57 Compared with DYT1 and location within the GP for the treatment of dyskinesias idiopathic cervical dystonia, the responses of non-DYT1 seems to be the ventral portion of the GPi. Some groups primary dystonias and secondary dystonias to surgery are have reported that stimulation of the GPe and the dorsal variable.1,7,13,15,19,27,34,36,37,47,59,71,83 Nonetheless, several pa- border of the GPi improves akinesia and worsens dyski- tients with a variety of non-DYT1 dystonias and sec- nesias.6,17,31 The results of GPi stimulation can be op- ondary dystonias, such as those seen in Hallervorden– timized by adjusting the device’s parameters and careful- Spatz syndrome,73,80 have benefited from GPi lesioning or ly choosing among the multiple contacts on the DBS DBS.28,35,44,64,69,74,81 electrode within the GPi. Use of Stereotactic Surgery for Dystonia. The surgical Targets for the treatment of dyskinesias and PD. The treatment of dystonia has a long history, beginning in the issue of whether the GPi or the STN is a better target for 1950s. In the past, the most common target for ablation the treatment of advanced PD and levodopa-induced was the thalamus. In one of the largest series of patients dyskinesias is still debated.16,32,36,40,77 The GP is a larger with dystonia who were treated with thalamotomies, structure and there is more heterogeneity in its response to Cooper14 reported an overall improvement in 70% of surgical interventions.4 This is probably related to varia- cases. Nevertheless, his procedures varied in location tions in the position of the stimulating electrode contacts within targets, by number of lesions, number of repeated in the pallidal complex.22,45 In contrast, the STN is smaller procedures, methods of ablation, and targeted nuclei, in- and appears to provide more consistent results.46 In the cluding the nuclei ventralis oralis anterior, ventralis oralis only prospective randomized study published so far, posterior, and ventralis intermedius, and centromedian, Burchiel, et al.,10 have shown that after 1 year dyskinesias the pulvinar, and portions of the nucleus ventralis postero- were improved by 67% with DBS of the STN and by 47% lateralis. Studies in which patients with dystonia were fur- with DBS of the GPi. This difference was not statistically ther subdivided according to type have shown that thala- significant because the study was underpowered; it in- motomies improved the dystonic symptoms in 25 to 80% cluded only 10 patients. A multicenter prospective non- of patients with generalized dystonia, in 33 to 62% of randomized cross-over study showed that dyskinesia those with focal/segmental dystonia, in 35 to 60% of scores improved by 58% with DBS of the STN and by patients with primary dystonia, and in 34 to 63% of those 66% with DBS of the GPi at 6 months.16 The time spent in with secondary dystonia.2,11,21,63,65,84 The nuclei ventralis the “on” condition with dyskinesias was reduced by 69% intermedius,2,65 ventralis oralis posterior,65 and the transi- with DBS of the STN and by 65% with DBS of the GPi at tional nucleus ventralis oralis anterior/posterior,11,84 were 6 months. Randomized double-blinded trials will be nec- the most common targets chosen for ablation. The major essary to evaluate the relative effectiveness of each of limitation of thalamotomies, particularly when they were these approaches in the treatment of levodopa-induced performed bilaterally, was the high incidence of compli- abnormal movements. cations including speech problems, motor weakness, and pseudobulbar palsy.2,11, 21,63,65,84 Even though in some of the older studies the GPi has also been reported as a target,14,23 USE OF DBS FOR DYSTONIA pallidal procedures for the treatment of dystonias have only recently regained attention.26,47 Dystonia Types. Dystonia is a syndrome of sustained Stimulation of the GPi. Patients with dystonia who muscle contractions that produces twisting and repetitive have significant disability and whose condition is resistant movements and abnormal postures.20 Various forms of to pharmacotherapy are considered to be surgical candi- dystonia have been described, most of which are refrac- dates. The main advantages of pallidal stimulation over tory to medical therapies. In this context, DBS has been pallidotomy are reversibility and the ability to adjust the used to treat several of these conditions but its efficacy desired parameters of stimulation. These characteristics varies according to the type of dystonia. may be important in younger patients or patients with sec- The common form of inherited generalized primary ondary dystonia in whom structural lesions already exist dystonia is the DYT1 form (Oppenheim dystonia).
Load more

Recommended publications
  • Primary Lateral Sclerosis, Upper Motor Neuron Dominant Amyotrophic Lateral Sclerosis, and Hereditary Spastic Paraplegia
    brain sciences Review Upper Motor Neuron Disorders: Primary Lateral Sclerosis, Upper Motor Neuron Dominant Amyotrophic Lateral Sclerosis, and Hereditary Spastic Paraplegia Timothy Fullam and Jeffrey Statland * Department of Neurology, University of Kansas Medical Center, Kansas, KS 66160, USA; [email protected] * Correspondence: [email protected] Abstract: Following the exclusion of potentially reversible causes, the differential for those patients presenting with a predominant upper motor neuron syndrome includes primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), or upper motor neuron dominant ALS (UMNdALS). Differentiation of these disorders in the early phases of disease remains challenging. While no single clinical or diagnostic tests is specific, there are several developing biomarkers and neuroimaging technologies which may help distinguish PLS from HSP and UMNdALS. Recent consensus diagnostic criteria and use of evolving technologies will allow more precise delineation of PLS from other upper motor neuron disorders and aid in the targeting of potentially disease-modifying therapeutics. Keywords: primary lateral sclerosis; amyotrophic lateral sclerosis; hereditary spastic paraplegia Citation: Fullam, T.; Statland, J. Upper Motor Neuron Disorders: Primary Lateral Sclerosis, Upper 1. Introduction Motor Neuron Dominant Jean-Martin Charcot (1825–1893) and Wilhelm Erb (1840–1921) are credited with first Amyotrophic Lateral Sclerosis, and describing a distinct clinical syndrome of upper motor neuron (UMN) tract degeneration in Hereditary Spastic Paraplegia. Brain isolation with symptoms including spasticity, hyperreflexia, and mild weakness [1,2]. Many Sci. 2021, 11, 611. https:// of the earliest described cases included cases of hereditary spastic paraplegia, amyotrophic doi.org/10.3390/brainsci11050611 lateral sclerosis, and underrecognized structural, infectious, or inflammatory etiologies for upper motor neuron dysfunction which have since become routinely diagnosed with the Academic Editors: P.
    [Show full text]
  • Management of Neurogenic Dysphagia
    694 Postgrad Med J 2001;77:694–699 Postgrad Med J: first published as 10.1136/pmj.77.913.694 on 1 November 2001. Downloaded from Management of neurogenic dysphagia A M O Bakheit Dysphagia is common in patients with neuro- of the cerebral cortex, basal ganglia, brain logical disorders. It may result from lesions in stem, cerebellum, and lower cranial nerves may the central or peripheral nervous system as well result in dysphagia. Degeneration of the as from diseases of muscle and disorders of the myenteric ganglion cells in the oesophagus, neuromuscular junction. Drugs that are com- muscle diseases and disorders of neuromusc- monly used in the management of neurological ular transmission, for example myasthenia conditions may also precipitate or aggravate gravis and Eaton-Lambers syndrome, are other swallowing diYculties in some patients. Neuro- less common causes. genic dysphagia often results in serious compli- cations, including pulmonary aspiration, dehy- CEREBRAL CORTEX dration, and malnutrition. These The commonest condition associated with complications are usually preventable if the dysphagia resulting from cortical lesions is stroke. Acute stroke is complicated by dys- dysphagia is recognised early and managed 1 appropriately. phagia in about 25%–42% of all cases. Dysphagia in these patients is usually associ- Physiological mechanisms of neurogenic ated with hemiplegia due to lesions of the brain stem or the involvement of one or both dysphagia The act of swallowing may be viewed as three hemispheres. However, on rare occasions, dys- discrete but inter-related physiological stages: phagia may be the sole manifestation of a cer- the oral, pharyngeal, and oesophageal phases.
    [Show full text]
  • ICD9 & ICD10 Neuromuscular Codes
    ICD-9-CM and ICD-10-CM NEUROMUSCULAR DIAGNOSIS CODES ICD-9-CM ICD-10-CM Focal Neuropathy Mononeuropathy G56.00 Carpal tunnel syndrome, unspecified Carpal tunnel syndrome 354.00 G56.00 upper limb Other lesions of median nerve, Other median nerve lesion 354.10 G56.10 unspecified upper limb Lesion of ulnar nerve, unspecified Lesion of ulnar nerve 354.20 G56.20 upper limb Lesion of radial nerve, unspecified Lesion of radial nerve 354.30 G56.30 upper limb Lesion of sciatic nerve, unspecified Sciatic nerve lesion (Piriformis syndrome) 355.00 G57.00 lower limb Meralgia paresthetica, unspecified Meralgia paresthetica 355.10 G57.10 lower limb Lesion of lateral popiteal nerve, Peroneal nerve (lesion of lateral popiteal nerve) 355.30 G57.30 unspecified lower limb Tarsal tunnel syndrome, unspecified Tarsal tunnel syndrome 355.50 G57.50 lower limb Plexus Brachial plexus lesion 353.00 Brachial plexus disorders G54.0 Brachial neuralgia (or radiculitis NOS) 723.40 Radiculopathy, cervical region M54.12 Radiculopathy, cervicothoracic region M54.13 Thoracic outlet syndrome (Thoracic root Thoracic root disorders, not elsewhere 353.00 G54.3 lesions, not elsewhere classified) classified Lumbosacral plexus lesion 353.10 Lumbosacral plexus disorders G54.1 Neuralgic amyotrophy 353.50 Neuralgic amyotrophy G54.5 Root Cervical radiculopathy (Intervertebral disc Cervical disc disorder with myelopathy, 722.71 M50.00 disorder with myelopathy, cervical region) unspecified cervical region Lumbosacral root lesions (Degeneration of Other intervertebral disc degeneration,
    [Show full text]
  • History-Of-Movement-Disorders.Pdf
    Comp. by: NJayamalathiProof0000876237 Date:20/11/08 Time:10:08:14 Stage:First Proof File Path://spiina1001z/Womat/Production/PRODENV/0000000001/0000011393/0000000016/ 0000876237.3D Proof by: QC by: ProjectAcronym:BS:FINGER Volume:02133 Handbook of Clinical Neurology, Vol. 95 (3rd series) History of Neurology S. Finger, F. Boller, K.L. Tyler, Editors # 2009 Elsevier B.V. All rights reserved Chapter 33 The history of movement disorders DOUGLAS J. LANSKA* Veterans Affairs Medical Center, Tomah, WI, USA, and University of Wisconsin School of Medicine and Public Health, Madison, WI, USA THE BASAL GANGLIA AND DISORDERS Eduard Hitzig (1838–1907) on the cerebral cortex of dogs OF MOVEMENT (Fritsch and Hitzig, 1870/1960), British physiologist Distinction between cortex, white matter, David Ferrier’s (1843–1928) stimulation and ablation and subcortical nuclei experiments on rabbits, cats, dogs and primates begun in 1873 (Ferrier, 1876), and Jackson’s careful clinical The distinction between cortex, white matter, and sub- and clinical-pathologic studies in people (late 1860s cortical nuclei was appreciated by Andreas Vesalius and early 1870s) that the role of the motor cortex was (1514–1564) and Francisco Piccolomini (1520–1604) in appreciated, so that by 1876 Jackson could consider the the 16th century (Vesalius, 1542; Piccolomini, 1630; “motor centers in Hitzig and Ferrier’s region ...higher Goetz et al., 2001a), and a century later British physician in degree of evolution that the corpus striatum” Thomas Willis (1621–1675) implicated the corpus
    [Show full text]
  • THE SYNDROMES of the ARTERIES of the BRAIN and SPINAL CORD Part 1 by LESLIE G
    65 Postgrad Med J: first published as 10.1136/pgmj.29.328.65 on 1 February 1953. Downloaded from THE SYNDROMES OF THE ARTERIES OF THE BRAIN AND SPINAL CORD Part 1 By LESLIE G. KILOH, M.D., M.R.C.P., D.P.M. First Assistant in the Joint Department of Psychological Medicine, Royal Victoria Infirmary and University of Durham Introduction general circulatory efficiency at the time of the Little interest is shown at present in the syn- catastrophe is of the greatest importance. An dromes of the arteries of the brain and spinal cord, occlusion, producing little effect in the presence of and this perhaps is related to the tendency to a normal blood pressure, may cause widespread minimize the importance of cerebral localization. pathological changes if hypotension co-exists. Yet these syndromes are far from being fully A marked discrepancy has been noted between elucidated and understood. It must be admitted the effects of ligation and of spontaneous throm- that in many cases precise localization is often of bosis of an artery. The former seldom produces little more than academic interest and ill effects whilst the latter frequently determines provides Protected by copyright. nothing but a measure of personal satisfaction to infarction. This is probably due to the tendency the physician. But it is worth recalling that the of a spontaneous thrombus to extend along the detailed study of the distribution of the bronchi affected vessel, sealing its branches and blocking and of the pathological anatomy of congenital its collateral circulation, and to the fact that the abnormalities of the heart, was similarly neglected arterial disease is so often generalized.
    [Show full text]
  • Part Ii – Neurological Disorders
    Part ii – Neurological Disorders CHAPTER 14 MOVEMENT DISORDERS AND MOTOR NEURONE DISEASE Dr William P. Howlett 2012 Kilimanjaro Christian Medical Centre, Moshi, Kilimanjaro, Tanzania BRIC 2012 University of Bergen PO Box 7800 NO-5020 Bergen Norway NEUROLOGY IN AFRICA William Howlett Illustrations: Ellinor Moldeklev Hoff, Department of Photos and Drawings, UiB Cover: Tor Vegard Tobiassen Layout: Christian Bakke, Division of Communication, University of Bergen E JØM RKE IL T M 2 Printed by Bodoni, Bergen, Norway 4 9 1 9 6 Trykksak Copyright © 2012 William Howlett NEUROLOGY IN AFRICA is freely available to download at Bergen Open Research Archive (https://bora.uib.no) www.uib.no/cih/en/resources/neurology-in-africa ISBN 978-82-7453-085-0 Notice/Disclaimer This publication is intended to give accurate information with regard to the subject matter covered. However medical knowledge is constantly changing and information may alter. It is the responsibility of the practitioner to determine the best treatment for the patient and readers are therefore obliged to check and verify information contained within the book. This recommendation is most important with regard to drugs used, their dose, route and duration of administration, indications and contraindications and side effects. The author and the publisher waive any and all liability for damages, injury or death to persons or property incurred, directly or indirectly by this publication. CONTENTS MOVEMENT DISORDERS AND MOTOR NEURONE DISEASE 329 PARKINSON’S DISEASE (PD) � � � � � � � � � � �
    [Show full text]
  • NEUROLOGY WEAKNESS PATTERNS First Determine If the Lesion Is Affects Upper Or Lower Motor Neurones
    NEUROLOGY WEAKNESS PATTERNS First determine if the lesion is affects upper or lower motor neurones: Upper Motor Neurone Lower Motor Neurone Tone ↑ ‘Spastic’ ↓ ‘Flaccid’ Weakness ‘Pyramidal’ pattern i.e. weakness of Focal pattern i.e. only muscles upper limb extensors, lower limb innervated by damaged neurones are flexors affected Coordination Reduced Reflexes Increased Reduced/ Absent Babinski Positive Negative Others Pronator drift Muscle wasting Clasp knife response (to removal of Fasciculations force) Fibrillations Causes Stroke/ traumatic brain injury Myasthenia gravis Motor Neurone Disease Motor Neurone Disease Multiple Sclerosis Cerebral Palsy CAP 37 HAP 33 Kevin Gervin 7/2/17 What do we mean by extrapyramidal? Extrapyramidal symptoms Symptoms affecting tracts other than corticospinal and corticobulbar Extrapyramidal tracts don’t travel through the medullary pyramids The system regulates posture and muscle tone so pathology usually leads to movement disorders Most common cause is typical antipsychotics affecting Dopamine (D2) receptors e.g. haloperidol Treatment is anticholinergics e.g. procyclidine Extrapyramidal conditions: Acute dystonic reactions → muscle spasms e.g. neck, jaw, back. Akathisia- feeling of internal restlessness Drug induced Parkinsonism- tremor, rigidity etc. Tardive dyskinesia- involuntary muscle movements of lower face and extremities, often permanent What’s the difference between a Bulbar and Pseudobulbar palsy? Bulbar Pseudobulbar Pathophysiology LMN lesion CN V, VII, IX- XII Disease of corticobulbar
    [Show full text]
  • Isolated Facial Palsy: a New Lacunar Syndrome
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.47.1.84 on 1 January 1984. Downloaded from Journal ofNeurology, Neurosuirgery, and Psychiatry 1984;47: 84-86 Short report Isolated facial palsy: a new lacunar syndrome CHENYA HUANG, GERALD BROE From the Department ofMedicine, University ofHong Kong, Queen Mary Hospital, Hong Kong and Department ofNeurology, Lidcombe Hospital, Lidcombe, Australia SUMMARY Three cases of sudden isolated upper motor neuron facial palsy and two with associated pseudobulbar palsy have been seen. All were without significant limb weakness. Computed tomography demonstrated small deep infarcts in the internal capsular/corona radiata regions. Pure upper motor neuron facial palsy may be another lacunar syndrome, due to a lesion in the internal capsule or corona radiata. palsies are lower motor neuron lesions. On examination blood pressure was 130/90 mm Hg. He Most facial facial paresis, complete an isolated facial palsy is seen had a left upper motor neuron Occasionally however, and aphagia. Jaw jerk was not increased. Tone, motor neuron in nature. anarthria which appears to be upper power, coordination and sensation were normal; however Protected by copyright. Prior to the availability of CT scan, the site of such the patient veered slightly to the left on walking. CSF lesion was unknown. Some have been ascribed to examination showed 1 mononuclear cell/mm' with normal peripheral facial nerve lesions. ' Puvenendren, Wong biochemistry and serology. EMG of facial muscles showed and Ransome described in 1979 five patients with no abnormality. CT scan showed small low density lesions sudden onset of dysarthria, dysphagia and upper bilaterally in the region of corona radiata adjacent to the motor neuron facial palsy.' EEG and isotope scans basal ganglia (fig 1).
    [Show full text]
  • Primary Lateral Sclerosis Presenting Parkinsonian Symptoms Without
    1768 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2003.035212 on 16 November 2004. Downloaded from SHORT REPORT Primary lateral sclerosis presenting parkinsonian symptoms without nigrostriatal involvement N Mabuchi, H Watanabe, N Atsuta, M Hirayama, H Ito, H Fukatsu, T Kato, K Ito, G Sobue ............................................................................................................................... J Neurol Neurosurg Psychiatry 2004;75:1768–1771. doi: 10.1136/jnnp.2003.035212 We encountered three patients with primary lateral sclerosis Patient 2 Frozen gait with initial hesitation developed at age 62, (PLS) showing bradykinesia, frozen gait, and severe postural followed by cramping in both legs during sleep at age 64. He instability, as well as slowly progressive spinobulbar began to experience speech disturbance with spastic dys- spasticity. Cranial magnetic resonance (MR) imaging showed arthria and bouts of unprovoked laughing and crying. He precentral gyrus atrophy. Central motor conduction was showed severe postural instability with occasional falling, markedly prolonged or failed to evoke a response. Positron especially backward, as well as akinesia. He could not stand emission tomography (PET) showed significant reduction of up or initiate walking smoothly. He also showed facial 18 [ F]fluoro-2-deoxy-D-glucose uptake in the area of the hypokinesia with reduced blinking. All symptoms showed precentral gyrus extending to the prefrontal, medial frontal, gradual progression. and cingulate areas. No abnormalities were seen in the nigrostriatal system with PET using [18F]fluorodopa or 11 Patient 3 [ C]raclopride or with proton MR spectroscopy. Thus, Postural instability and gait disturbance were present by age widespread prefrontal, medial, and cingulate frontal lobe 68. He noted left arm clumsiness, and paucity of movement involvement can be associated with the parkinsonian gradually worsened and progressed to akinesia.
    [Show full text]
  • Pathological Laughter and Crying in Patients with Multiple System Atrophy-Cerebellar Type
    Movement Disorders Vol. 22, No. 6, 2007, pp. 798–803 © 2007 Movement Disorder Society Pathological Laughter and Crying in Patients with Multiple System Atrophy-Cerebellar Type Josef Parvizi, MD, PhD,1* Jeffrey Joseph, MD, PhD,1 Daniel Z. Press, MD,1 and Jeremy D. Schmahmann, MD2 1Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA 2Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA Abstract: In the cerebellar type of multiple system atrophy or crying, or both in 9 more patients. Our finding of about (MSA-C), the burden of pathological changes involves the 36% occurrence suggests that the problem of dysregulation cerebellum and its associated brainstem structures in the of emotional expression is more prevalent in MSA-C basis pontis and the inferior olivary nucleus, and as a result, than the paucity of reports in the literature suggests. Our the clinical phenotype is dominated early on by the cerebel- findings are consistent with the view that the cerebellum and lar dysfunction. We report our clinical and post mor- its interconnected structures may be involved in the regula- tem findings in a patient with MSA-C who exhibited patho- tion of emotional expression. © 2007 Movement Disorder logical laughter in the absence of any congruent changes of Society mood. A review of the clinical notes of 27 other patients Key words: olivopontocerebellar atrophy; disinhibition; with MSA-C revealed a problem with pathological laughter, emotion; behavior; pseudobulbar affect Pathological laughter and crying (PLC) is a condition Numerous terms have been introduced to describe the in which a patient with an underlying neurological dis- problem of inappropriate or exaggerated laughing and order exhibits episodes of laughter or crying or both, crying.
    [Show full text]
  • The Management of Motor Neurone Disease
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.74.suppl_4.iv32 on 1 December 2003. Downloaded from THE MANAGEMENT OF MOTOR NEURONE DISEASE P N Leigh, S Abrahams, A Al-Chalabi, M-A Ampong, iv32 L H Goldstein, J Johnson, R Lyall, J Moxham, N Mustfa, A Rio, C Shaw, E Willey, and the King’s MND Care and Research Team J Neurol Neurosurg Psychiatry 2003;74(Suppl IV):iv32–iv47 he management of motor neurone disease (MND) has evolved rapidly over the last two decades. Although still incurable, MND is not untreatable. From an attitude of nihilism, Ttreatments and interventions that prolong survival have been developed. These treatments do not, however, arrest progression or reverse weakness. They raise difficult practical and ethical questions about quality of life, choice, and end of life decisions. Coordinated multidisciplinary care is the cornerstone of management and evidence supporting this approach, and for symptomatic treatment, is growing.1–3 Hospital based, community rehabilitation teams and palliative care teams can work effectively together, shifting emphasis and changing roles as the needs of the individuals affected by MND evolve. In the UK, MND care centres and regional networks of multidisciplinary teams are being established. Similar networks of MND centres exist in many other European countries and in North America. Here, we review current practice in relation to diagnosis, genetic counselling, the relief of common symptoms, multidisciplinary care, the place of gastrostomy and assisted ventilation, the use of riluzole, and end of life issues. c TERMINOLOGY c Motor neurone disease (MND) is a synonym for amyotrophic lateral sclerosis (ALS).
    [Show full text]
  • A Dictionary of Neurological Signs.Pdf
    A DICTIONARY OF NEUROLOGICAL SIGNS THIRD EDITION A DICTIONARY OF NEUROLOGICAL SIGNS THIRD EDITION A.J. LARNER MA, MD, MRCP (UK), DHMSA Consultant Neurologist Walton Centre for Neurology and Neurosurgery, Liverpool Honorary Lecturer in Neuroscience, University of Liverpool Society of Apothecaries’ Honorary Lecturer in the History of Medicine, University of Liverpool Liverpool, U.K. 123 Andrew J. Larner MA MD MRCP (UK) DHMSA Walton Centre for Neurology & Neurosurgery Lower Lane L9 7LJ Liverpool, UK ISBN 978-1-4419-7094-7 e-ISBN 978-1-4419-7095-4 DOI 10.1007/978-1-4419-7095-4 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2010937226 © Springer Science+Business Media, LLC 2001, 2006, 2011 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made.
    [Show full text]